CD24 and neoplasm: IMM47, developed by YiMab, is a pioneering anti-CD24 monoclonal antibody in China for clinical trials, showing tumor eradication in preclinical studies.116 Pheast Therapeutics, founded by a key figure in CD24 research, has raised substantial funds for drug development.117 OncoC4 advances a varied pipeline, including CAR-T and bispecific antibodies, towards clinical trials.118 These drugs target the CD24 protein to enhance immune responses against tumors.